Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial

JAMA

Volumn 284, Issue 4, 2000, Pages 472-477

  Hadigan, Colleen ^a   Corcoran, Colleen ^a   Basgoz, Nesli ^a   Davis, Benjamin ^a   Sax, Paul ^a   Grinspoon, Steven ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; METFORMIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034718193     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidemia, and diabetes mellitus. Lancet. 1999;353:2093-2099.
2. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 1999;21:107-113.
3. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral treatment. AIDS. 1999; 13:465-471.
4. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-I infection. Lancet. 1998;351:867-870.
5. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal fat accumulation associated with use of indinavir. Lancet. 1998;351:871-875.
6. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 1998;27:65-67.
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitor therapy. AIDS. 1998;12:F51-F58.
8. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease-inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet. 1998;352:1881-1883.
9. Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in HIV-infected women. J Clin Endocrinol Metab. 1999;84:1932-1937.
10. Hadigan C, Corcoran C, Stanley T, et al. Fasting hyperinsulinemia in HIV-infected men. J Clin Endocrinol Metab. 2000;85:35-41.
11. Vigouroux C, Gharakhanian S, Salhi Y, et al. Diabetes, insulin resistance and dyslipidemia in lipodystrophic HIV-infected patient on highly active antiretroviral therapy (HAART). Diabetes Metab. 1999;25:225-232.
12. Walli RK, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS. 1998;12:F167-F173.
13. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor. Acta Med Scand. 1985;5701:38-52.
14. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease in healthy middle aged men. Circulation. 1998;98:398-404.
15. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
16. WHO Expert Committee on Diabetes Mellitus: second report. World Health Organ Tech Rep Ser. 1980; 646:1-80.
17. Borkan GA, Gerzof SG, Robbins AH, Silbert CK, Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr. 1982;36:172-177.
18. Walli RK, Michl GM, Bogner JR, Goebel FD. Effects of the PPAR-activator troglitazone on protease inhibitor associated peripheral insulin resistance. Paper presented at: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill.
19. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS. 1999;13:1000-1002.
20. Defronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
21. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy. Lancet. 1999;354:1112-1115.
22. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 1997; 46:454-457.
23. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body mass index and mortality in a prospective cohort of US adults. N Engl J Med. 1999;341:1097-1105.
24. Stokes JL, Kannel WB, Wolf PA, et al. Blood pressure as a risk factor for cardiovascular disease: the Framingham Study. Hypertension. 1989;13(suppl 5):13-18.
25. Anderson RL, Hamman RF, Savage PJ, et al. Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests. Am J Epidemiol. 1995;142:724-732.
26. Peiris AN, Sothman MS, Hoffman RG, et al. Adiposity, fat distribution and cardiovascular risk. Ann Intern Med. 1989;110:867-872.